Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
10 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/10/3096394/0/en/HepaRegeniX-Doses-First-Patient-in-Phase-Ib-Trial-with-Small-Molecule-Inhibitor-HRX-215-to-Promote-Liver-Regeneration.html
08 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/08/3077246/0/en/HepaRegeniX-Scientific-Founder-Covers-HRX-215-Development-and-Clincial-Data-in-Plenary-at-the-European-Association-for-the-Study-of-the-Liver-Congress-2025.html
15 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/15/3061487/0/en/HepaRegeniX-completes-21-5-million-financing-to-support-clinical-advancement-of-HRX-215-for-liver-regeneration.html
10 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/10/2910869/0/en/HepaRegeniX-raises-15-million-Series-C-round-to-advance-clinical-development-of-HRX-215-for-liver-regeneration.html
14 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/03/14/2846504/0/en/HepaRegeniX-publishes-data-for-its-first-in-class-MKK4-inhibitor-HRX-215-for-the-treatment-of-acute-and-chronic-liver-diseases-in-Cell.html
30 Mar 2022
// ACCESSWIRE
https://www.accesswire.com/695217/HepaRegeniX-Appoints-Elias-Papatheodorou-as-New-Chairman-of-the-Board-of-Directors
ABOUT THIS PAGE